UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/596,432	06/13/2006	Nicolas Burdin	06-439	6546
	7590 09/09/200 BOEHNEN HULBER	EXAMINER		
300 S. WACKE		YOUNG, SHAWQUIA		
32ND FLOOR CHICAGO, IL	60606		ART UNIT	PAPER NUMBER
			1626	
			MAIL DATE	DELIVERY MODE
			09/09/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.		Applicant(s)					
Office Action Summary			10/596,432		BURDIN ET AL.				
			Examiner		Art Unit				
			SHAWQUIA Y	OUNG/	1626				
Period fo	The MAILING DATE of this commu r Reply	nication appe	ears on the co	ver sheet with the c	orrespondence ad	ddress			
WHIC - Exter after - If NO - Failur Any r	ORTENED STATUTORY PERIOD F HEVER IS LONGER, FROM THE IN Isions of time may be available under the provision: SIX (6) MONTHS from the mailing date of this coming period for reply is specified above, the maximum is the to reply within the set or extended period for reply eply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	MAILING DAT s of 37 CFR 1.136 munication. tatutory period will y will, by statute, ca	TE OF THIS 5(a). In no event, I I apply and will expanse the application	COMMUNICATION nowever, may a reply be tin pire SIX (6) MONTHS from on to become ABANDONE	N. nely filed the mailing date of this of (35 U.S.C. § 133).				
Status									
1) 又	Responsive to communication(s) file	ed on <i>04 Jun</i>	ne 2008						
′=	This action is FINAL . 2b) This action is non-final.								
′=		<i>'</i> —			secution as to the	e merits is			
٥,,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)⊠	Claim(s) 1-6 is/are pending in the a	pplication.							
	4a) Of the above claim(s) is/are withdrawn from consideration.								
	5) Claim(s) is/are allowed.								
	Claim(s) <u>1-6</u> is/are rejected.								
· ·	Claim(s) is/are objected to.								
-	Claim(s) are subject to restri	ction and/or e	election requ	irement.					
	on Papers								
	The specification is objected to by the	o Evaminor							
•	The drawing(s) filed on <u>13 June 200</u>			or h) Ohiected to	by the Evaminer				
10/63					-				
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority u	nder 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (I nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date <u>6/13/06</u> .		4) 5) 6)	☐ Interview Summary Paper No(s)/Mail Da ☐ Notice of Informal F ☐ Other:	ate				

DETAILED ACTION

Claims 1-6 are currently pending in the instant application. Applicants have cancelled claims 7 and 8 in a preliminary amendment.

I. Priority

The instant application is a 371 of PCT/FR04/03308, filed on December 20, 2004 and claims benefit of Foreign Application FRANCE 0314995, filed on December 19, 2003.

II. Information Disclosure Statement

The information disclosure statement (IDS) submitted on August 1, 2007 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner.

III. Restriction/Election

A. Election: Applicant's Response

Applicants' election without traverse of an immunostimulant composition comprising 4-amino-2-ethoxymethyl- α , α -dimethyl-1-H-imidazo[4,5c]quinoline-1-ethanol, a Toll-like 7 receptor agonist and ER804057, a Toll-like 4 receptor agonist in the reply filed on June 4, 2008 is acknowledged.

Subject matter not encompassed by elected Group above are withdrawn from further consideration pursuant to 37 CFR 1.142 (b), as being drawn to nonelected inventions.

IV. Rejections

Claim Rejections - 35 USC § 112, 1st paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 4-6 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The "imidazoquinolineamine derivatives" of the of Claim 4 are not defined in the specification so as to know the structures of the compounds that are included and/or excluded by the term. Therefore, the specification lacks adequate support for Claims 4-6.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-6 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, the terms "Toll-like 7 receptor", "Toll-like 8 receptor" and "Toll-like 4 receptor" found in claim 1 and the phrase renders the products indefinite as the above terms can be considered open-ended language when not clearly defined and therefore is including additional subject matter in the

compositions claimed in claim 1 that is not described in the instant specification and is not particularly pointed out or distinctly claimed. A claim to a compound in a composition cannot be open-ended, but must be claimed with precision.

Claims 4-6 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 4-6 are indefinite for the reasons set forth above under 35 U.S.C. 112, first paragraph. Claim 4 contains the limitation that the agonist of the Toll-like 7 receptor is an imidazoquinolineamine derivative. However, the "imidazoquinolineamine derivative" in Claims 4-6 are not defined in the claims so as to know the metes and bounds of the claims. Therefore, the claims are indefinite.

Claims 5 and 6 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, claim 5 depends on the "preceding claim" but there are 4 claims that precede claim 5 and it is unclear what claim that claims 5 depends on. Therefore, the claims are indefinite.

V. Objections

Claim Objection-Non Elected Subject Matter

Claims 1-6 are objected to as containing non-elected subject matter. To overcome this objection, Applicant should submit an amendment deleting the non-elected subject matter.

Application/Control Number: 10/596,432 Page 5

Art Unit: 1626

VI. Conclusion

Any inquiry concerning this communication or earlier communications from

the examiner should be directed to Shawquia Young whose telephone number is 571-

272-9043. The examiner can normally be reached on 7:00 AM-3:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Joseph M[©]Kane can be reached on 571-272-0699. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

/Shawquia Young/

Examiner, Art Unit 1626

/Kamal A Saeed, Ph.D./

Primary Examiner, Art Unit 1626